Unknown

Dataset Information

0

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.

ABSTRACT:

SUBMITTER: Barouch DH 

PROVIDER: S-EPMC8314733 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.
| S-EPMC8282116 | biostudies-literature
Unknown Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
| S-EPMC9239277 | biostudies-literature
Unknown Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination.
| S-EPMC8635656 | biostudies-literature
Unknown Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.
| S-EPMC8063883 | biostudies-literature
Unknown Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S.
| S-EPMC9258461 | biostudies-literature
Unknown Bell's palsy following the Ad26.COV2.S COVID-19 vaccination.
| S-EPMC8244554 | biostudies-literature
Unknown Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.
| S-EPMC5319823 | biostudies-literature
Unknown Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer.
| S-EPMC8117965 | biostudies-literature
Unknown Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination.
| S-EPMC8421108 | biostudies-literature
Unknown Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.
| S-EPMC7522255 | biostudies-literature